nach oben

Clinical Pharmacokinetics

Erschienen in:

04.05.2019 | Original Research Article

Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients

verfasst von: Yan Rong, Patrick Mayo, Mary H. H. Ensom, Tony K. L. Kiang

Erschienen in: Clinical Pharmacokinetics | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Background and Objective

Mycophenolic acid is commonly prescribed to adult kidney transplant recipients. Mycophenolic acid is extensively metabolized to mycophenolic acid-glucuronide (major metabolite) and mycophenolic acid-acyl-glucuronide (minor metabolite). We hypothesized that (1) adult kidney transplant patients on corticosteroid-free regimens exhibit unique mycophenolic acid population pharmacokinetics compared with patients receiving corticosteroid-based therapy, and (2) mycophenolic acid clearance is directly dependent on glucuronide metabolite formation.

Methods

Non-linear mixed-effects modeling was conducted with MonolixSuite-2018R1 (n = 27). Optimal pharmacokinetic models were selected based on objective function values, standard errors, and biological plausibility.

Results

Clinical demographic data were sex (female, 16), age (47 ± 13 years, mean ± standard deviation), weight (70 ± 16 kg), height (165 ± 9 cm), albumin (43 ± 4 g/L), serum creatinine (102 ± 27 µmol/L), estimated glomerular filtration rate (61 ± 16 mL/min/1.73 m²), mycophenolic acid dosage (1.4 ± 0.5 g/day, as mycophenolate mofetil), and tacrolimus dosage (5 ± 3 mg/day, immediate release). The population pharmacokinetics of mycophenolic acid can be described by a two-compartment first-order absorption with lag time, and a linear elimination structural model. The apparent oral clearance estimate in the final model (population mean, relative standard error) was 2.87 L/h, 42.3%, which is lower than that reported for similar patients on corticosteroid-based regimens (11.9–26.3 L/h). Other pharmacokinetic parameters were comparable to historical data obtained in corticosteroid-based patients. Both mycophenolic acid-acyl-glucuronide trough concentration and the area under the concentration–time curve ratio were significant covariates that reduced mycophenolic acid apparent oral clearance from 16.5 (base model) to 2.87 L/h. The model was evaluated based on bootstrapping, visual predictive checks, and diagnostic plots.

Conclusions

Our novel findings suggest the potential need to reduce mycophenolic acid dosage in subjects on corticosteroid-free regimens. Corticosteroid-free subjects may also be more sensitive to drug/gene interactions.

Kiang TKL, Ensom MHH. Population pharmacokinetics of mycophenolic acid: an update. Clin Pharmacokinet. 2018;57(5):547–58.PubMed

Kiang TKL, Ensom MHH. Anti-rejection drugs. In: Murphy J, editor. Clinical pharmacokinetics. Bethesda: American Society of Health-System Pharmacists; 2017. pp. 205–20.

Kiang TKL, Ensom MH. Immunosuppressants. In: Beringer P, editor. Basic clinical pharmacokinetics. Philadelphia: Wolters Kluwer; 2017. pp. 320–58.

Kiang TKL, Ensom MHH. Therapeutic drug monitoring of mycophenolate in adult solid organ transplant patients: an update. Expert Opin Drug Metab Toxicol. 2016;12(5):545–53.PubMed

Staatz CE, Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol. 2014;88(7):1351–89.PubMed

Kiang TKL, Partovi N, Shapiro RJ, Berman JM, Collier AC, Ensom MHH. Regression and genomic analyses on the association between mycophenolic acid exposure and absolute neutrophil count in steroid-free, de novo kidney transplant recipients. Clin Drug Investig. 2018;38(11):1011–22.PubMed

Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J, FREEDOM Study Group. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant. 2008;8(2):307–16.PubMed

Lemieux I, Houde I, Pascot A, Lachance JG, Noel R, Radeau T, et al. Effects of prednisone withdrawal on the new metabolic triad in cyclosporine-treated kidney transplant patients. Kidney Int. 2002;62(5):1839–47.PubMed

Andrade-Sierra J, Rojas-Campos E, Cardona-Munoz E, Evangelista-Carrillo LA, Puentes-Camacho A, Lugo-Lopez O, et al. Early steroid withdrawal in a renal transplant cohort treated with tacrolimus, mycophenolate mofetil and basiliximab. Nefrologia. 2014;34(2):216–22.PubMed

10.

Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13–8.PubMed

11.

Soars MG, Petullo DM, Eckstein JA, Kasper SC, Wrighton SA. An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos. 2004;32(1):140–8.PubMed

12.

Qadri I, Hu LJ, Iwahashi M, Al-Zuabi S, Quattrochi LC, Simon FR. Interaction of hepatocyte nuclear factors in transcriptional regulation of tissue specific hormonal expression of human multidrug resistance-associated protein 2 (abcc2). Toxicol Appl Pharmacol. 2009;234(3):281–92.PubMed

13.

Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002;62(3):1060–7.PubMed

14.

Greanya ED, Poulin E, Partovi N, Shapiro RJ, Al-Khatib M, Ensom MH. Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. Am J Health Syst Pharm. 2012;69(2):134–42.PubMed

15.

Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011;50(1):1–24.PubMedPubMedCentral

16.

Staatz CE, Tett SE. Maximum a posteriori Bayesian estimation of mycophenolic acid area under the concentration-time curve: is this clinically useful for dosage prediction yet? Clin Pharmacokinet. 2011;50(12):759–72.PubMed

17.

Dong M, Fukuda T, Vinks AA. Optimization of mycophenolic acid therapy using clinical pharmacometrics. Drug Metab Pharmacokinet. 2014;29(1):4–11.PubMed

18.

Yu ZC, Zhou PJ, Wang XH, Francoise B, Xu D, Zhang WX, et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients. Acta Pharmacol Sin. 2017;38(11):1566–79.PubMedPubMedCentral

19.

Colom H, Andreu F, van Gelder T, Hesselink DA, de Winter BCM, Bestard O, et al. Prediction of free from total mycophenolic acid concentrations in stable renal transplant patients: a population-based approach. Clin Pharmacokinet. 2018;57(7):877–93.PubMed

20.

Chen B, Shao K, An HM, Shi HQ, Lu JQ, Zhai XH, et al. Population pharmacokinetics and bayesian estimation of mycophenolic acid exposure in Chinese renal allograft recipients after administration of EC-MPS. J Clin Pharmacol. 2019;59(4):578–89.PubMed

21.

Yau WP, Vathsala A, Lou HX, Zhou S, Chan E. Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients. J Clin Pharmacol. 2009;49(6):684–99.PubMed

22.

de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodyn. 2009;36(6):541–64.PubMedPubMedCentral

23.

Cremers S, Schoemaker R, Scholten E, den Hartigh J, Konig-Quartel J, van Kan E, et al. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br J Clin Pharmacol. 2005;60(3):249–56.PubMedPubMedCentral

24.

Musuamba FT, Rousseau A, Bosmans JL, Senessael JJ, Cumps J, Marquet P, et al. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. Clin Pharmacokinet. 2009;48(11):745–58.PubMed

25.

Sam WJ, Akhlaghi F, Rosenbaum SE. Population pharmacokinetics of mycophenolic acid and its 2 glucuronidated metabolites in kidney transplant recipients. J Clin Pharmacol. 2009;49(2):185–95.PubMed

26.

Colom H, Lloberas N, Andreu F, Caldes A, Torras J, Oppenheimer F, et al. Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. Kidney Int. 2014;85(6):1434–43.PubMed

27.

de Winter BC, Mathot RA, Sombogaard F, Vulto AG, van Gelder T. Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. Clin J Am Soc Nephrol. 2011;6(3):656–63.PubMedPubMedCentral

28.

de Winter BC, Mathot RA, Sombogaard F, Neumann I, van Hest RM, Doorduijn JK, et al. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease. Ther Drug Monit. 2010;32(5):606–14.PubMed

29.

de Winter BC, Monchaud C, Premaud A, Pison C, Kessler R, Reynaud-Gaubert M, et al. Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients. Clin Pharmacokinet. 2012;51(1):29–39.PubMed

30.

de Winter BC, van Gelder T, Glander P, Cattaneo D, Tedesco-Silva H, Neumann I, et al. Population pharmacokinetics of mycophenolic acid: a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. Clin Pharmacokinet. 2008;47(12):827–38.PubMed

31.

Staatz CE, Duffull SB, Kiberd B, Fraser AD, Tett SE. Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. Eur J Clin Pharmacol. 2005;61(7):507–16.PubMed

32.

Velickovic-Radovanovic RM, Jankovic SM, Milovanovic JR, Catic-Dordevic AK, Spasic AA, Stefanovic NZ, et al. Variability of mycophenolic acid elimination in the renal transplant recipients: population pharmacokinetic approach. Ren Fail. 2015;37(4):652–8.PubMed

33.

Shum B, Duffull SB, Taylor PJ, Tett SE. Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol. 2003;56(2):188–97.PubMedPubMedCentral

34.

Musuamba FT, Mourad M, Haufroid V, Demeyer M, Capron A, Delattre IK, et al. A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic acid and tacrolimus early after renal transplantation. J Clin Pharmacol. 2012;52(12):1833–43.PubMed

35.

Lamba M, Tafti B, Melcher M, Chan G, Krishnaswami S, Busque S. Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients. Ther Drug Monit. 2010;32(6):778–81.PubMed

36.

Guillet BA, Simon NS, Purgus R, Botta C, Morange S, Berland Y, et al. Population pharmacokinetics analysis of mycophenolic acid in adult kidney transplant patients with chronic graft dysfunction. Ther Drug Monit. 2010;32(4):427–32.PubMed

37.

Han N, Yun HY, Kim IW, Oh YJ, Kim YS, Oh JM. Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients. Eur J Clin Pharmacol. 2014;70(10):1211–9.PubMed

38.

Funaki T. Enterohepatic circulation model for population pharmacokinetic analysis. J Pharm Pharmacol. 1999;51(10):1143–8.PubMed

39.

van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006;17(3):871–80.PubMed

40.

van Hest RM, van Gelder T, Bouw R, Goggin T, Gordon R, Mamelok RD, et al. Time-dependent clearance of mycophenolic acid in renal transplant recipients. Br J Clin Pharmacol. 2007;63(6):741–52.PubMedPubMedCentral

41.

van Hest RM, van Gelder T, Vulto AG, Mathot RA. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2005;44(10):1083–96.PubMed

42.

Le Guellec C, Buchler M, Giraudeau B, Le Meur Y, Gakoue JE, Lebranchu Y, et al. Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. Eur J Clin Pharmacol. 2002;57(11):805–11.PubMed

43.

Ting LS, Partovi N, Levy RD, Riggs KW, Ensom MH. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients. Ther Drug Monit. 2008;30(3):282–91.PubMed

44.

Ting LS, Decarie D, Ensom MH. Effect of acidification on protein binding of mycophenolic acid. Ther Drug Monit. 2007;29(1):132–3.PubMed

45.

LIXOFT. Monolix Suite 2018. http://www.lixoft.com. Accessed 01 Jun 2018.

46.

Kiang TKL, Sherwin CM, Spigarelli MG, Ensom MHH. Fundamentals of population pharmacokinetic modelling: modelling and software. Clin Pharmacokinet. 2012;51(8):515–25.PubMed

47.

Sherwin CM, Kiang TKL, Spigarelli MG, Ensom MHH. Fundamentals of population pharmacokinetic modelling: validation methods. Clin Pharmacokinet. 2012;51(9):573–90.PubMed

48.

Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol. 2012;1:e6.PubMedPubMedCentral

49.

Rong Y, Mayo P, Ensom MHH, Kiang TKL. Population pharmacokinetic analysis of immediate-release oral tacrolimus co-administered with mycophenolate mofetil in corticosteroid-free adult kidney transplant recipients. Eur J Drug Metab Pharmacokinet. 2018. https://doi.org/10.1007/s13318-018-0525-3.CrossRef

50.

R Core Team. R software v3.4.2. 2018. https://www.R-project.org. Accessed 02 Aug 2018.

51.

Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558–69.PubMedPubMedCentral

52.

Tedesco-Silva H, Bastien MC, Choi L, Felipe C, Campestrini J, Picard F, et al. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil. Transplant Proc. 2005;37(2):852–5.PubMed

53.

Usui T, Kuno T, Mizutani T. Induction of human UDP-glucuronosyltransferase 1A1 by cortisol-GR. Mol Biol Rep. 2006;33(2):91–6.PubMed

54.

Kanou M, Usui T, Ueyama H, Sato H, Ohkubo I, Mizutani T. Stimulation of transcriptional expression of human UDP-glucuronosyltransferase 1A1 by dexamethasone. Mol Biol Rep. 2004;31(3):151–8.PubMed

55.

Ashraf MN, Asghar MW, Rong Y, Doschak MR, Kiang TKL. Advanced in vitro HepaRG culture systems for xenobiotic metabolism and toxicity characterization. Eur J Drug Metab Pharmacokinet. 2018;78:98. https://doi.org/10.1007/s13318-018-0533-3.CrossRef

56.

Mackenzie PI. Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. Ther Drug Monit. 2000;22(1):10–3.PubMed

57.

Miles KK, Stern ST, Smith PC, Kessler FK, Ali S, Ritter JK. An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: evidence for a principal role of UGT1A enzymes and species differences in UGT1A specificity. Drug Metab Dispos. 2005;33(10):1513–20.PubMed

58.

Bernard O, Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos. 2004;32(8):775–8.PubMed

59.

Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005;33(1):139–46.PubMed

60.

Bernard O, Tojcic J, Journault K, Perusse L, Guillemette C. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab Dispos. 2006;34(9):1539–45.PubMed

61.

Johnson LA, Oetting WS, Basu S, Prausa S, Matas A, Jacobson PA. Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors. Eur J Clin Pharmacol. 2008;64(11):1047–56.PubMed

62.

Vanhove T, Bouwsma H, Hilbrands L, Swen JJ, Spriet I, Annaert P, et al. Determinants of the magnitude of interaction between tacrolimus and voriconazole/posaconazole in solid organ recipients. Am J Transplant. 2017;17(9):2372–80.PubMed

63.

Atcheson BA, Taylor PJ, Kirkpatrick CM, et al. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit. 2004;26(3):284–6.PubMed

64.

Li P, Shuker N, Hesselink DA, van Schaik RH, Zhang X, van Gelder T. Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients? Transpl Int. 2014;27(10):994–1004.PubMed

Titel: Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients
verfasst von: Yan Rong
Patrick Mayo
Mary H. H. Ensom
Tony K. L. Kiang
Publikationsdatum: 04.05.2019
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 11/2019
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-019-00771-3

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients

Abstract

Background and Objective

Methods

Results

Conclusions

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background and Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2019

Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis

Immune Checkpoint Inhibitors in Melanoma: A Review of Pharmacokinetics and Exposure–Response Relationships

What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review

The Effect of Food Intake on the Pharmacokinetics of Oral Basal Insulin: A Randomised Crossover Trial in Healthy Male Subjects

Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures

Requirements to Establishing Confidence in Physiologically Based Pharmacokinetic (PBPK) Models and Overcoming Some of the Challenges to Meeting Them